Scinai Immunotherapeutics Ltd.

Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.

SCNI | US

Overview

Corporate Details

ISIN(s):: US09073Q3039 (+1 more)
LEI:
Country:: United States of America
Address:: JERUSALEM BIOPARK, 2ND FLOOR, 0 JERUSALEM
Website:: https://www.scinai.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Scinai Immunotherapeutics is a biopharmaceutical company with a dual business model focused on inflammation and immunology (I&I). The company develops a proprietary pipeline of biological products, including alpaca-derived nanosized antibodies (NanoAbs) for autoimmune and infectious diseases, in collaboration with institutions like the Max Planck Institute. Additionally, its Scinai Bio-services business unit operates as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive services to other pharmaceutical and biotech companies. These services span process and analytical development, scale-up, and cGMP manufacturing for nonclinical and clinical studies from its state-of-the-art facility.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Scinai Immunotherapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Scinai Immunotherapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Scinai Immunotherapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.	Türkiye	GENIL
Genmab Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.	Denmark	GMAB
GENOLUTION INC. Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.	South Korea	225220
Genome&Company Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.	South Korea	314130
Genomictree Inc. Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.	South Korea	228760
Genomtec S.A. Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.	Poland	GMT
GENOTECH CORP. A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.	South Korea	066830
Genprex, Inc. A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.	United States of America	GNPX
Gentian Diagnostics ASA Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.	Norway	GENT
GERON CORP Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.	United States of America	GERN